Abstract: Peptide receptor radionuclide therapy (PRRT), being investigated as an effective treatment for inoperable gastroenteropancreatic neuroendocrine tumor, has gained much importance in recent years. With increasing data of clinical trials and the exploration of different radionuclides as well as the toxic and side effects, PRRT has developed continuously and play a marked role on the treatment of gastroenteropancreatic neuroendocrine tumor.